Evidence map›Paper›PMID 16799139›Full record

ReviewThe journals of gerontology. Series A, Biological sciences and medical sciences2006

Interleukin-6 in aging and chronic disease: a magnificent pathway.

Marcello Maggio, Jack M Guralnik, Dan L Longo, Luigi Ferrucci

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journals of gerontology. Series A, Biological sciences and medical sciences, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 360 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
360citing papers in PubMed, 6 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

360 citing papers in PubMed, 6 syntheses or guidelines pooled it, 704 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Review

300 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Marcello MaggioClinical Research Branch, Longitudinal Studies Section, National Institute on Aging, National Institutes of Health, Baltimore, MD 21225, USA.
Jack M Guralnik
Dan L Longo
Luigi Ferrucci
National Institutes of Health · USMedStar Union Memorial Hospital · US

Funding

Intramural NIH HHS Z99 AG999999
6 · The paper itself

Abstract

The human interleukin IL-6 was originally cloned in 1986. In 1993, William Ershler, in his article "IL-6: A Cytokine for Gerontologists," indicated IL-6 as one of the main signaling pathways modulating the complex relationship between aging and chronic morbidity. Over the last 12 years, our understanding of the role of IL-6 in human physiology and pathology has substantially grown, although some of the questions originally posed by Ershler are still debated. In this review, we will focus on IL-6 structure, IL-6 signaling, and trans signaling pathways, and the role of IL-6 in geriatric syndromes and chronic disease. In the final section of this review, we dissect the critical elements of the IL-6 signaling pathway and point out targets for intervention that are targeted by emerging drugs, some still on the horizon and others already being tested in clinical trials.

Indexed as

Chronic DiseaseAgingBiomarkersHumansInterleukin-6Signal TransductionBiomarkersInterleukin-6

Identifiers

PMID16799139
PMCPMC2645627
OpenAlexW2098930053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.